EC approves Vertex's KALYDECO for treatment of cystic fibrosis
20:43 EDT 27 Jul 2012 | The Medical News
Vertex Pharmaceuticals Incorporated announced today that the European Commission has approved KALYDECOTM (ivacaftor) for people with cystic fibrosis (CF) ages 6 and older who have at least one copy of the G551D mutation in the cystic fibrosis transme..
Original Article: EC approves Vertex's KALYDECO for treatment of cystic fibrosis
More From BioPortfolio on "EC approves Vertex's KALYDECO for treatment of cystic fibrosis"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
